Activity Overview
This online, on-demand virtual symposium brings together renowned experts in EGFR-mutated non–small cell lung cancer. In this educational program, these experts use real-world patient scenarios to examine adjuvant vs neoadjuvant therapy in an early-stage setting; evidence supporting monotherapy and combination regimens in frontline treatment, including chemotherapy and amivantamab-based regimens; and current and emerging options in common patient treatment journeys.
This educational activity is an archive of the live symposium held on February 19, 2026.
Target Audience
This educational activity is directed toward medical and thoracic oncologists, pulmonologists, pathologists, advanced practice providers, nurses, pharmacists, and other health care providers involved in the management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret recent clinical trial safety and efficacy data for agents being studied in early-stage and advanced EGFR-mutated NSCLC
- Formulate appropriate strategies for the management of adverse effects related to EGFR-targeted therapies in advanced NSCLC
- Develop individualized first-line treatment plans for patients with early-stage and advanced EGFR-mutant NSCLC by implementing new data and guideline-recommended strategies
Jonathan Riess, MD, MS
Director,
Thoracic Oncology
Associate
Profess of Medicine
UC Davis Comprehensive
Cancer Center
Sacramento,
CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foundation Medicine, Janssen, Merck, Nuvalent, OncoHost, Pfizer, Taiho Pharmaceuticals, Verastem; Grant/Research Funding: AstraZeneca, Bicycle Therapeutics, Janssen, Merck, Novartis, Nuvalent, Pfizer, Prelude, Revolution Medicine, Summit
Fawzi Abu Rous, MD
Thoracic
Medical Oncologist
Henry Ford
Health
Detroit, MI
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Johnson & Johnson, Merus, Pfizer, Rigel Pharmaceuticals, Servier
Julia Rotow, MD
Assistant
Professor
Harvard
Medical School
Clinical
Director, Lowe Center for Thoracic Oncology
Dana-Farber
Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Amgen, AstraZeneca, BioAtla, BlossomHill, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, G1 Therapeutics, Genentech, Gilead Sciences, Guardant Health, Jazz Pharmaceuticals, Johnson & Johnson, Merus, Novocure, Nuvalent, Nuvation Bio, Pfizer, Regeneron, Sanofi-Genzyme, Summit Therapeutics, Takeda; Grant/Research Funding: AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond, BlossomHill, Blueprint Medicines, Bristol Myers Squibb, DualityBio, Enliven Therapeutics, EpimAb, ImmunityBio, Loxo Oncology, ORIC Pharmaceuticals, RedCloud Bio, Summit, Synthekine, Regeneron
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
